FDA Invites AI-Identified Drug Candidates for Further Study

US-FEDNOTABLEGuidanceHealthcare AI

What changed

FDA guidance invites submission of drug candidates identified through high-throughput screening, in vitro models, or AI/ML-based pre-clinical data, even where no clinical evidence yet exists.

Who this touches

Drug developers and researchers using AI/ML tools to identify pre-clinical candidates.

Why it matters

The pathway lets sponsors bring forward AI/ML-flagged candidates lacking clinical evidence, provided the pre-clinical data are promising enough to merit further study.

Suggested next step — and why

Developers with AI-derived pre-clinical leads might use this guidance to structure submissions around the strength of that pre-clinical data.

The clock

No new dates specified in the guidance.

Source: Primary source on file — read in the original, not from coverage.

Permanent record: this page is public forever. "When did we know?" always has a URL.

Curated nightly by Dr. Ivan Del Valle — AI governance architect, editor of The Compact. Disagree with a reading? Write ivan.delvalle@rsit.ai — every message is read, most are answered. Corrections are published, not buried. · Today's brief · Method · Reporting free forever; the desk is sustained by its data plans.